"Obama health plan not likely to embrace long-term care"

15 December 2008

If US citizens have been putting off getting long-term care insurance, should they delay it a bit longer, anticipating the new administration's health plan? "I wouldn't advise it," says Denise Gott, chairman of the board of LTC Financial Partners, one of the nation's insurance agencies. "Long-term care has never been a part of any candidate's overall health care reform proposal, and likely never will be," she adds.

Why not? "The country is split over the degree to which the government should be involved in our health care system, and this is reflected in Congress," Ms Gott says, noting that "fiscally conservative Democrats, allied with Republicans, will question a big-ticket package for basic health care, let alone expanding to include long term care."

The cost of health care reform will be huge, and would be much larger with long-term care included. "If the Obama administration's health proposal moves forward in its current form,"Ms Gott says, "it will easily cost $100.0 billion per year to fund. If you added in the cost of long-term care services, the total outlay would easily double." That is extremely unlikely to happen, she points out. In addition to the natural resistance of conservatives in Congress, there is an additional challenge. "If you give doctors, hospitals, drug companies, insurers and all the others what they want to get them on board, you will create an enormously expensive bill and subsequent opposition. That's why the California health bill failed earlier this year when the total costs became clear," she contends (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight